Literature DB >> 7170790

Disposition and metabolism of formoterol fumarate, a new bronchodilator, in rats and dogs.

H Sasaki, H Kamimura, Y Shiobara, Y Esumi, M Takaichi, T Yokoshima.   

Abstract

1. The disposition and metabolism of formoterol fumarate, a highly potent beta 2-adrenoceptor stimulant, were studied in rats and dogs. 2. After oral administration of [3H] formoterol fumarate to dogs, unchanged formoterol accounted for greater than 60% of the plasma radioactivity immediately after dosage; greater than 20% was due to the unchanged drug until 12 h after dosage. In contrast, only 1-3% of the radioactivity was present as unchanged drug in rat plasma. After i.v. dosage, unchanged drug was much higher in both species. The elimination half-life of formoterol was 4-6 h in dogs and 1.7 h in rats. 3. In both species, 36-45% of the dose was excreted in urine and 50-56% in faeces in 72 h, irrespective of the administration route. Biliary excretion after oral dosage amounted to 65 and 31% in rats and dogs, respectively. 4. T.l.c. before and after enzymic hydrolysis revealed that the drug was excreted in urine and bile of rats mostly as a conjugate. Dog urine also contained the conjugate but the unchanged drug was much higher than in rats. The conjugated metabolite was purified from rat urine and identified as the 2-O-glucuronide. The glucuronide was the only metabolite detected in the urine and bile of rats and in the urine of dogs.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7170790     DOI: 10.3109/00498258209038952

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  2 in total

Review 1.  Formoterol. A review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease.

Authors:  D Faulds; L M Hollingshead; K L Goa
Journal:  Drugs       Date:  1991-07       Impact factor: 9.546

2.  Formoterol PLGA-PEG Nanoparticles Induce Mitochondrial Biogenesis in Renal Proximal Tubules.

Authors:  Ernest L Vallorz; Karen Blohm-Mangone; Rick G Schnellmann; Heidi M Mansour
Journal:  AAPS J       Date:  2021-06-24       Impact factor: 3.603

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.